While IL-6 mRNA was equivalent in both groups, decreased expression of its downstream intracellular effector may decrease atrogin-1 expression and down-regulate the acute phase response, thereby addressing the proportion of sarcopenia that is driven by inflammation25, 49. Here, FBXO32 is linked to sarcopenia.